SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema

Clare Bailey; Marion R. Munk; Varun Chaudhary; C. Lange; Hassiba Oubraham; Peter Morgan-Warren; Helmut Allmeier; Tobias Machewitz; Sarah Schlief; Rose Gilbert; Susanne Oesch; Martin Kirchner; Zoran Hasanbasic; Paolo Lanzetta; on behalf of the SPECTRUM study investigators; Adrian Fung; Amy Cohn; Andrew Chang; Devinder Chauhan; G. Liew; Jennifer Arnold; Paul Mitchell; Sanjeewa Wickremasinghe; Arif Samad; Brian Ballios; Cynthia Qian; David Lederer; Donald Nixon; Keyvan Koushan; Netan Choudhry; Parnian Arjmand; Raman Tuli; Robert Gizicki; Sohel Somani; Thomas Sheidow; Varun Chaudhary; Wai Ching Lam; Lasse Jørgensen Cehofski; M Lytken Larsen; Michael Spangsberg; Hannele Uusitalo‐Järvinen; Raimo Tuuminen; Alexandre Bourhis; Aude Couturier; Audrey Giocanti‐Auregan; Benjamin Wolff; Corinne Dot; David Sayag; Eric Souied; F. De Bats; F. Becquet; Frédéric Matonti; Hassiba Oubraham-Mebroukine; Hessam Razavi; Isabelle Aubry-Quenet; Joël Uzzan; Laurent Berthon; Laurent Kodjikian; L. Vélasque; Marie-Noelle Delyfer; Mathieu Lehmann; Mathilde Gallice; Mélanie Tessier; Olivia Zambrowski; Philippe Schauer; Pierre-Henry Gabrielle; Salomon Cohen; Stéphanie Baillif; Thi Ha Chau Tran; Vincent Gualino; Xavier Benouaich; Alexander Daudrich; Andreas Berlin; Andreas Stahl; Astrid Sader-Moritz; Ben Mehrinfar; Christian Karl Brinkmann; Christoph Arnholdt; C. Lange; Costin-Ilie Mihaescu; Erik Beeke; Fabian Höhn; Hüsnü Berk; Ines Lanzl; J Wachtlin; Kai Januschowski; Katrin Lorenz; Marc Schargus; Maria-Andreea Gamulescu; Nikolaus Feucht; Oliver Zeitz; Philipp Müller; Ralf Schmitt; Roxana Fulga; Sabine Baumgarten; Simo Murovski; Stefan Schrader; Svenja Deuchler; Tim U. Krohne; Tobias Duncker

doi:10.1038/s41433-026-04659-y

July 11, 2026EyeOpen Access

SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the early clinical experience of aflibercept 8 mg in patients with diabetic macular oedema.
Global study of aflibercept 8 mg for diabetic macular oedema and neovascular age-related macular degeneration
Involves treatment-naïve and previously treated patients
Analysis of real-world clinical practice outcomes
Early experience suggests positive outcomes in treatment-naïve patients
Effectiveness of aflibercept in routine clinical settings is promising
Data highlight the potential of aflibercept for managing diabetic macular oedema

Implication

Global study evaluates aflibercept 8 mg's effectiveness for diabetic macular oedema, suggesting positive early outcomes.

Abstract

The PHOTON Phase 2/3 trial demonstrated the efficacy and safety of intravitreal aflibercept 8 mg in the treatment of diabetic macular oedema (DME) [ 1 ]. SPECTRUM is a global study evaluating aflibercept 8 mg treatment of DME and neovascular age-related macular degeneration (nAMD) in routine clinical practice. This SPECTRUM analysis presents early clinical experience with aflibercept 8 mg among patients with treatment-naïve (TN) or previously treated (PT) DME.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bailey et al. (2026) studied this question.

synapsesocial.com/papers/6a54835d475c38bf615a5eff https://doi.org/10.1038/s41433-026-04659-y

View Full Paper

Ask AI

Bookmark

Share

SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema

Key Points

Implication

Abstract

Discussion

Cite This Study

SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading